-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The field of gene editing has been heating up in recent years with the rise of companies such as Intellia and CRISPR Therapeutics
.
Now, two small biotech companies will join forces in a $45 million research deal to boost each other's competitiveness
Myeloid and Prime will collaborate to optimize Myeloid's RetroT™ technology with the goal of applying it to multiple cell types, increasing its efficiency and expanding its programmability, allowing targeting to pre-specified targets in the genome
.
The breakthrough technology, which implants gene-sized pieces of DNA into the genome, has the potential to dramatically expand the type and range of genetic errors that can be reversed in situ
Myeloid's R&D pipeline
Prime Editing, developed by scientific founders David R.
Liu, PhD, and Andrew Anzalone, PhD, of the Broad Institute of MIT and Harvard, leverages a proprietary technology platform, Prime Editing, to find the exact spot to edit in the genome position and replace the defective DNA segment with the correct DNA copy
.
Multiple drug discovery programs are currently advancing for liver, eye, ex vivo hematopoietic stem cells and neuromuscular indications
The technical process of Prime Editing
Gene editing is a genetic engineering technology that can modify specific genes in an organism's genome.
With the advancement of gene editing technology and the development of vectors, the market size of gene and cell therapy continues to expand
.
According to FDA estimates, by 2025, 10-20 gene and cell therapy products will be approved each year, and there is still a lot of room for growth in the future
In the early industry, techniques such as ES cell targeting were commonly used for gene editing, but the success rate was low
.
After the popularization of CRISPR gene editing technology in 2012, the production cost, gene editing accuracy, and production cycle of model organisms were effectively reduced, the cost was greatly reduced, and large-scale production was possible, so it began to be widely used in drug research and development and life science research
Therefore, with the deepening of research in this field, a series of companies have been derived to update and iterate on the way of gene editing
.
Recently, an editing tool called AIMers published in a sub-journal of Nature has also attracted the attention of the industry
Although the research on editing tools such as RetroT and AIMers is relatively preliminary, more experiments are needed to test their functions and safety
.
But there is no doubt that they enrich existing gene-editing systems
